Logo image of PGEN

PRECIGEN INC (PGEN) Stock Fundamental Analysis

USA - NASDAQ:PGEN - US74017N1054 - Common Stock

3.25 USD
-0.08 (-2.4%)
Last: 10/3/2025, 8:00:01 PM
3.2399 USD
-0.01 (-0.31%)
After Hours: 10/3/2025, 8:00:01 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to PGEN. PGEN was compared to 536 industry peers in the Biotechnology industry. Both the profitability and financial health of PGEN have multiple concerns. While showing a medium growth rate, PGEN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PGEN has reported negative net income.
PGEN had a negative operating cash flow in the past year.
In the past 5 years PGEN reported 4 times negative net income.
PGEN had a negative operating cash flow in each of the past 5 years.
PGEN Yearly Net Income VS EBIT VS OCF VS FCFPGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M -400M -500M

1.2 Ratios

The Return On Assets of PGEN (-122.18%) is worse than 80.04% of its industry peers.
Industry RankSector Rank
ROA -122.18%
ROE N/A
ROIC N/A
ROA(3y)-45.76%
ROA(5y)-43.42%
ROE(3y)-82.57%
ROE(5y)-117.47%
ROIC(3y)N/A
ROIC(5y)N/A
PGEN Yearly ROA, ROE, ROICPGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PGEN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PGEN Yearly Profit, Operating, Gross MarginsPGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

PGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PGEN has been reduced compared to 1 year ago.
The number of shares outstanding for PGEN has been reduced compared to 5 years ago.
PGEN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PGEN Yearly Shares OutstandingPGEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
PGEN Yearly Total Debt VS Total AssetsPGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

PGEN has an Altman-Z score of -26.86. This is a bad value and indicates that PGEN is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -26.86, PGEN is not doing good in the industry: 87.69% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -26.86
ROIC/WACCN/A
WACC9.98%
PGEN Yearly LT Debt VS Equity VS FCFPGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

PGEN has a Current Ratio of 2.71. This indicates that PGEN is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.71, PGEN is not doing good in the industry: 67.54% of the companies in the same industry are doing better.
PGEN has a Quick Ratio of 2.71. This indicates that PGEN is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.71, PGEN is not doing good in the industry: 65.49% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.71
Quick Ratio 2.71
PGEN Yearly Current Assets VS Current LiabilitesPGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 24.39% over the past year.
Looking at the last year, PGEN shows a decrease in Revenue. The Revenue has decreased by -1.14% in the last year.
Measured over the past years, PGEN shows a very negative growth in Revenue. The Revenue has been decreasing by -46.64% on average per year.
EPS 1Y (TTM)24.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
Revenue 1Y (TTM)-1.14%
Revenue growth 3Y-35.01%
Revenue growth 5Y-46.64%
Sales Q2Q%19.39%

3.2 Future

The Earnings Per Share is expected to grow by 35.65% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 162.26% on average over the next years. This is a very strong growth
EPS Next Y-16.57%
EPS Next 2Y-43.51%
EPS Next 3Y41.94%
EPS Next 5Y35.65%
Revenue Next Year229.22%
Revenue Next 2Y413.09%
Revenue Next 3Y305.36%
Revenue Next 5Y162.26%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PGEN Yearly Revenue VS EstimatesPGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
PGEN Yearly EPS VS EstimatesPGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PGEN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PGEN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PGEN Price Earnings VS Forward Price EarningsPGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PGEN Per share dataPGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as PGEN's earnings are expected to grow with 41.94% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-43.51%
EPS Next 3Y41.94%

More info and screens

0

5. Dividend

5.1 Amount

PGEN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PRECIGEN INC

NASDAQ:PGEN (10/3/2025, 8:00:01 PM)

After market: 3.2399 -0.01 (-0.31%)

3.25

-0.08 (-2.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-12 2025-11-12/amc
Inst Owners56.44%
Inst Owner Change1.57%
Ins Owners2.78%
Ins Owner Change3.37%
Market Cap968.40M
Analysts80
Price Target8.41 (158.77%)
Short Float %13.25%
Short Ratio3.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.74%
Min EPS beat(2)-6.73%
Max EPS beat(2)14.22%
EPS beat(4)1
Avg EPS beat(4)-1.68%
Min EPS beat(4)-10.29%
Max EPS beat(4)14.22%
EPS beat(8)1
Avg EPS beat(8)-10.67%
EPS beat(12)2
Avg EPS beat(12)-34.53%
EPS beat(16)5
Avg EPS beat(16)-22.22%
Revenue beat(2)2
Avg Revenue beat(2)94.41%
Min Revenue beat(2)25.88%
Max Revenue beat(2)162.94%
Revenue beat(4)2
Avg Revenue beat(4)37.5%
Min Revenue beat(4)-25.25%
Max Revenue beat(4)162.94%
Revenue beat(8)2
Avg Revenue beat(8)1.81%
Revenue beat(12)2
Avg Revenue beat(12)-12.53%
Revenue beat(16)2
Avg Revenue beat(16)-30.35%
PT rev (1m)0%
PT rev (3m)37.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-20.16%
EPS NY rev (1m)0%
EPS NY rev (3m)-48.15%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.57%
Revenue NY rev (1m)0%
Revenue NY rev (3m)36.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 223.13
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.31
EYN/A
EPS(NY)-0.72
Fwd EYN/A
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS0.01
BVpS-0.02
TBVpS-0.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -122.18%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.76%
ROA(5y)-43.42%
ROE(3y)-82.57%
ROE(5y)-117.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 134.85%
Cap/Sales 80.6%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.71
Quick Ratio 2.71
Altman-Z -26.86
F-Score5
WACC9.98%
ROIC/WACCN/A
Cap/Depr(3y)86.13%
Cap/Depr(5y)70.81%
Cap/Sales(3y)87.22%
Cap/Sales(5y)63.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
EPS Next Y-16.57%
EPS Next 2Y-43.51%
EPS Next 3Y41.94%
EPS Next 5Y35.65%
Revenue 1Y (TTM)-1.14%
Revenue growth 3Y-35.01%
Revenue growth 5Y-46.64%
Sales Q2Q%19.39%
Revenue Next Year229.22%
Revenue Next 2Y413.09%
Revenue Next 3Y305.36%
Revenue Next 5Y162.26%
EBIT growth 1Y0.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.62%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y7.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.67%
OCF growth 3YN/A
OCF growth 5YN/A